Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-I, Taq-I & Bsm-I) with susceptibility of benign prostatic hyperplasia in a North Indian population

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 1005-1008

  Manchanda, Parmeet Kaur ^a   Konwar, Rituraj ^b   Lakshma Nayak, V ^b   Singh, Vishwajeet ^c   Bid, Hemant Kumar ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Benign prostatic hyperplasia; PCR RFLP; Polymorphism; VDR

Indexed keywords

EID: 78650702483     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Adorini L, Penna G, Amuchastegui S (2007). Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol, 103, 689-93.
2. Bid HK, Mishra DK, Mittal RD (2005). Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev, 6, 147-52.
3. Blazer DG 3rd, Umbach DM, Bostick RM (2000). Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinogenesis, 27, 18-23.
4. Bousema TJ, Bussemakers MJG, van Houwelingen KP (2000). Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol, 37, 234-8.
5. Crescioli C, Maggie M, Vannelli GB (2000). Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab, 85, 2576-83.
6. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B (2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev, 7, 136-9.
7. Feldman D, Malloy PJ, Gross C (2001). Vitamin D: biology, action and clinical implications. In: Marcus R, Feldman D and Kelsey J (Eds). Osteoporosis. Academic Press, San Diego.
8. Hammarsten J, Damber JE, Johnell O (2006). A low vitamin D level is an independent risk factor for the development of benign prostatic hyperplasia. Urology, 68, 5.
9. Hamasakia T, Inatomia H, Katohb T (2002). Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int, 68, 226-31.
10. Habuchi T, Suzuki T, Sasaki R (2000). Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res, 60, 305-8.
11. Huang S, Huang C, Wu W (2006). Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer, 119, 1902-7.
12. Krill D, DeFlavia P, Dhir R (2001). Expression patterns of vitamin D receptor in human Prostate. J Cell Biochem, 82, 566-72.
13. Konety BR, Schwartz GG, Acierno JS (1996). The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ, 7, 1563-70.
14. Konwar R, Chattopadhyay N, Bid HK (2008). Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int, 102, 536-44.
15. Lohmueller KE, Pearce CL, Pike M (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet, 33, 177-82.
16. Risch NJ (2000). Searching for genetic determinants in the new millennium. Nature, 405, 847-56.
17. Zamuda JM, Cauley JA, Ferrell RE (2000). Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev, 22, 203-17.